Skip to main content
Caplight Logo









Oblenio Bio

Oblenio Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.obleniobio.com/

Last Round

Series B

Jun 25, 2026

Total Funding Raised

$62M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Oblenio Bio is a biotechnology company developing LBL-051, a tri-specific T-cell engager antibody, for the treatment of autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

tri-specific antibodyT-cell engagerautoimmune disease therapyB-cell depletionimmunotherapyimmune resetantibody therapydrug developmentCD19 targetBCMA targetbiologicspre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oblenio Bio Comparables

Compare Oblenio Bio with similar companies based on industry and business-model similarity.

Oblenio Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Boulevard Bio
91%
Kali Therapeutics
86%
Gilead Sciences
82%

Oblenio Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 25, 2026
Series ANov 7, 2024

Key People

Founding team and executive leadership

Samantha Truex

CEO-in-Residence, CEO of Oblenio Bio

Executive Team

Oblenio Bio Investors

Notable investors and investment history

Oblenio Bio investors
InvestorRounds
Aditum BioSeries B, Series A
GVSeries B
Deep Track CapitalSeries B
Pfizer VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2026

    Grew 100% QoQ from 5 to 10 employees.

  • Jul 30, 2026

    Monthly visitors grew 657% MoM, reaching 2.7K.

Oblenio Bio Filings

Explore SEC and related filing metadata, where available.

Oblenio Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Oblenio Bio's valuation, stock price, and market status.

Is Oblenio Bio a public or private company?

Oblenio Bio is a private company.

What is the current stock price of Oblenio Bio?

Oblenio Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Oblenio Bio worth (valuation)?

Valuation information for Oblenio Bio is not publicly available.

Can I buy Oblenio Bio stock?

Oblenio Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Oblenio Bio's last funding round?

Oblenio Bio's most recent funding round was Series B on June 25, 2026.

Who are the main investors in Oblenio Bio?

Key investors in Oblenio Bio include Aditum Bio, Pfizer Ventures.

Will Oblenio Bio IPO soon?

No public IPO plans have been announced for Oblenio Bio.

How can I track Oblenio Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oblenio Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range5
Year Founded2024
Last FundingJun 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?